Back to the Top
The following message was posted to: PharmPK
On the subject of inhibitors, this time what does the team think
about a 2C19 pure inhibitor in a drug interaction volunteer study. We
are currently scheduled to use fluvoxamine.
Graham Mould
Graham Mould
Guildford Clinical Pharmacology Unit
Surrey Technology Centre
40 Occam Road
Guildford, GU2 7YG
Surrey
Tel: 01483 688304
fax: 01483 455375
Back to the Top
Graham,
Ticlopidine is a more selective inhibitor of CYP 2C19 although
perhaps less suitable than fluvoxamine for your clinical study.
Regards,
Peter
Peter W. Mullen, PhD, FCSFS
KEMIC BIORESEARCH
Kentville
Nova Scotia, B4N 4H8
Canada
Tel.: 902-678-8195 Fax: 902-678-2839 Email: pmullen.aaa.kemic.com
PharmPK Discussion List Archive Index page
Copyright 1995-2010 David W. A. Bourne (david@boomer.org)